Rituximab treatment for a patient with type I cryoglobulinemic glomerulonephritis

[1]  M. Veneziano,et al.  Efficacy of low-dose rituximab for mixed cryoglobulinemia. , 2007, Clinical immunology.

[2]  D. Gladstone,et al.  Severe, refractory, non-malignant type I cryoglobulinemia treated with alemtuzumab , 2007, Rheumatology International.

[3]  E. Kimby.  Tolerability and safety of rituximab (MabThera). , 2005, Cancer treatment reviews.

[4]  V. Dhillon,et al.  Eosinophilic fasciitis and eosinophilic colitis: a rare association. , 2005, Rheumatology.

[5]  G. Mazzucco,et al.  Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  E. Lerut,et al.  Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  R. Fanin,et al.  Efficacy and safety of rituximab in type II mixed cryoglobulinemia. , 2003, Blood.

[8]  Felicia A Tucci,et al.  Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. , 2003, Blood.

[9]  D. Droz,et al.  Renal involvement in monoclonal (type I) cryoglobulinemia: two cases associated with IgG3 kappa cryoglobulin. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  H. Liebman,et al.  Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab) , 2002, Annals of the rheumatic diseases.

[11]  Taal Bg,et al.  Cryoglobulins in primary biliary cirrhosis: prevalence and modulation by immunosuppressive therapy. , 1985 .

[12]  C. Mukhtyar,et al.  Rituximab inefficiency during type I cryoglobulinaemia , 2022 .